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Abstract
Background: Chronic fatigue syndrome (CFS) is an illness in search of an infectious etiology. GB
virus-C (GBV-C) virus is a flavivirus with cell tropism and host defense induction qualities
compatible with a role in producing the syndrome. The GBV-C genome is detectable in 4% of the
population and 12% of the population is seropositive. The present study evaluated the association
between infection with GBV and CFS.
Methods: We used a commercial EIA to detect antibodies against the GBV-C E2 protein and a
quantitative real-time RT-PCR assay to detect active GBV-C infection. Sera were from a case
control study of CFS in Atlanta, Georgia. The Fisher's exact two-tailed test was used for statistical
analysis.
Results: Two of 12 CFS patients and one of 21 controls were seropositive for prior GBV-C
infection and one control had viral RNA detected, indicating active infection. The results are not
statistically different.
Conclusion: We found no evidence that active or past infection with GBV is associated with CFS.
Background
Chronic fatigue syndrome (CFS) affects 400,000 to
900,000 adults in the United States [1,2]. At least a quarter
of those suffering from CFS are unemployed or receiving
disability because of the illness; the average affected fam-
ily forgoes $20,000 annually in lost earnings and wages
(approximately half of the average United States house-
hold income); and, the annual value of lost productivity
in the United States is approximately $9 billion [2-4].
Despite the public health burden imposed by CFS, diag-
nostic, treatment and prevention strategies have proven
difficult to devise because the etiology, pathophysiology
and risk factors of CFS remain unknown [reviewed in [5]].
Because the symptoms resemble those of infectious dis-
eases and because CFS may follow an acute infectious dis-
ease, a considerable body of work has attempted to
identify persistent or reactivated infection in patients with
this illness [reviewed in [5]]. These efforts have included
analysis of seroprevalence, evaluation of viral RNA and
DNA (i.e., latent/active infection), and most recently,
molecular identification procedures for unique, previ-
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ously uncharacterized pathogens [6-12]. None of these
reports have developed convincing evidence for a signifi-
cant association between any infectious agent and CFS.
However, negative, inconclusive, and conflicting case con-
trol studies do not mean that infectious etiologies for CFS
should be dismissed. A recently discovered flavivirus, GB
virus-C/HGV (GBV-C) [13-17], has many properties that
demanded a study assessing its possible association with
CFS. GBV-C preferentially replicates in peripheral blood
mononuclear cells (PBMC), primarily B and T lym-
phocytes, and in bone marrow in vivo [18,19]. Of note,
some flaviviruses activate the classic complement path-
way [20] and we have found a high prevalence of split
products (C3a, C4a, and C5a) in patients with CFS com-
pared to controls [21]. We have also examined mononu-
clear cell populations for gene expression patterns and
have found differences between patients and control sub-
jects [22,23]. GBV-C viremia may persist for several years
following primary infection and serologically antibodies
are generated against the envelope protein, E2 [reviewed
in [15,18]]. The antibodies are also long-lived and may
protect against re-infection [24]. GBV-C viremia and pres-
ence of antibodies are usually mutually exclusive, and
only a small percentage of exposed individuals exhibit
both viremia and anti-E2 antibody [25]. As yet, no illness
has been associated with GBV infection.
Therefore, thinking that complement activation and
altered mononuclear cell gene expression might reflect
continued infection with this virus, we chose to evaluate
banked serum specimens from subjects enrolled in a case
control study for GBV-C RNA, an indication of persistent
active infection that might be associated with CFS and for
specific antibodies associated with clearance of a GBV-C
infection (anti-E2) as an indicator of past infection with
this virus.
Methods
This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services
and the Helsinki Declaration. The CDC Institutional
Review Board approved study protocols. All participants
were volunteers who gave informed consent.
Study subjects
Subjects and study design have been presented in detail
elsewhere [25,26]. In brief, 26 patients with CFS (23
women and 3 men) were recruited from a physician sur-
veillance study in Atlanta [26]. Patients met the 1988 CFS
research case definition [27] and had been ill for no more
than 10 years. Two age-(± 5 years), race-, and sex-matched
nonfatigued control subjects were contacted by means of
random-digit dialing in the Atlanta area. Subjects' clinical,
seroepidemiologic [6], and immunological characteristics
have been reported [28]. For the current pilot study, testa-
ble sera were available from 12 cases and 21 controls.
Laboratory procedures
Detection of GBV-C infection
Plasma samples were tested for antibodies against the
GBV-C E2 envelope protein by a µPLATE Anti-HGenv
microtiter assay (Roche Diagnostics Corp., Indianapolis,
Ind.). Furthermore, nucleic acids were extracted from 200
µL of plasma by using the QIAamp Viral RNA Mini Kit
(Qiagen Inc., Valencia, Calif.), as per the manufacturer's
recommendations. A real-time quantitative reverse-tran-
scriptase polymerase chain reaction (qRT-PCR) was devel-
oped to detect GBV-C and determine the GBV-C viral
load. Five microliters of extracted nucleic acids were used
in the qRT-PCR assay, performed in a final volume of 50
µL using the Quantitect Probe RT-PCR kit (Qiagen). The
primers used were: GBV-C 03.1-F – 5' GCACGGTC-
CACAGGTGTT 3' (nucleotides 226-243 of the sequence
with GenBank accession number U44402[14] and GBV-C
03.2-R – 5' GTACGTGGGCGTCGTTTG 3' (nucleotides
313–330). The probe used had the sequence 5'
CCGACGTCAGGCTCGTCGTTAAAC 3' (nucleotides 268–
291), and was labeled with 6-carboxy-fluorescein (FAM)
on the 5' end and a dark quencher on the 3' end. This
combination of primers resulted in an amplicon of 105
base pairs (bp). Serial dilutions of in vitro transcribed RNA
generated from a linearized plasmid encoding nucleotides
136–400 of the 5' UTR of GBV-C with GenBank accession
number U44402[14] was used as a quantitative standard
curve.
Statistics
Based on the estimated prevalence of GBV-C (< 4%) in
healthy blood donors in the US [29], the available sample
size of 12 CFS subjects and 21 controls should allow
detection of 60 % positivity in viremia or positive serology
at the 95% confidence level with a power of 80: with at
least 50% of persons with CFS demonstrating viremia.
These estimates are based on the assumption that if GBV-
C infection is the primary cause CFS, the majority of CFS
subjects would be positive in one of the assay systems.
Results were analyzed using Fisher's exact test (2-tailed).
Odds ratios were calculated from a Chi square table and
confidence intervals defined using the Wald statistic.
Results and discussion
Two cases (16.7%) and 1 control (4.8%) were seroposi-
tive (2-tailed Fisher's exact test p = .54). Only one person
(a control subject) had detectable GBV-C RNA. Although
the odds ratio of this difference is 5.14, the confidence
interval (CI 0.32–49.59) demonstrates the difference was
statistically insignificant.BMC Infectious Diseases 2005, 5:78 http://www.biomedcentral.com/1471-2334/5/78
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This exploratory study did not identify significant differ-
ences in active or cleared GBV-C infections between indi-
viduals fulfilling a clinical definition of CFS or in control
subjects. These data would not exclude GBV-C infection in
small percentages (<20%) of CFS patients.
Since previous studies that used seropositivity or gene
expression alone have failed to demonstrate an associa-
tion between specific infections and CFS, we reasoned
that a combined serological and virological approach
would be more appropriate since only ongoing infection
with GBV-C is associated with viremia. These results are
consistent with values reported in a variety of population
studies regarding the prevalence of GBV-C. Previous stud-
ies have addressed Herpesviridae, enteroviruses, retrovi-
ruses, hepatitis C, HTLV-II [5] and recently parvovirus
[30] and Borna virus [31], but no definitive causative links
have been made. Thus, another attempt to link a majority
of CFS cases with a specific infectious agent did not iden-
tify a specific association.
Conclusion
CFS remains a clinically identifiable, but daunting, medi-
cal and psychological problem.
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